A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

BACKGROUND: We completed a phase I clinical trial to test the safety and toxicity of combined treatment with cixutumumab (anti-IGF-1R antibody) and selumetinib (MEK 1/2 inhibitor). METHODS: Patients with advanced solid tumours, refractory to standard therapy received selumetinib hydrogen sulphate ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilky, B A, Rudek, M A, Ahmed, S, Laheru, D A, Cosgrove, D, Donehower, R C, Nelkin, B, Ball, D, Doyle, L A, Chen, H, Ye, X, Bigley, G, Womack, C, Azad, N S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453594/
https://www.ncbi.nlm.nih.gov/pubmed/25268371
http://dx.doi.org/10.1038/bjc.2014.515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453594/
https://www.ncbi.nlm.nih.gov/pubmed/25268371
http://dx.doi.org/10.1038/bjc.2014.515

Ejemplares similares